SI3356385T1 - 18F-označeni inhibitorji prostatnih membranskih antigenov (PSMA) in njihova uporaba kot slikovno prikazna sredstva za rak prostate - Google Patents
18F-označeni inhibitorji prostatnih membranskih antigenov (PSMA) in njihova uporaba kot slikovno prikazna sredstva za rak prostateInfo
- Publication number
- SI3356385T1 SI3356385T1 SI201631064T SI201631064T SI3356385T1 SI 3356385 T1 SI3356385 T1 SI 3356385T1 SI 201631064 T SI201631064 T SI 201631064T SI 201631064 T SI201631064 T SI 201631064T SI 3356385 T1 SI3356385 T1 SI 3356385T1
- Authority
- SI
- Slovenia
- Prior art keywords
- psma
- imaging agents
- specific membrane
- membrane antigen
- prostate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15002800 | 2015-09-30 | ||
EP16164090 | 2016-04-06 | ||
EP16182764 | 2016-08-04 | ||
EP16778680.5A EP3356385B1 (en) | 2015-09-30 | 2016-09-19 | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer |
PCT/EP2016/001573 WO2017054907A1 (en) | 2015-09-30 | 2016-09-19 | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3356385T1 true SI3356385T1 (sl) | 2021-04-30 |
Family
ID=57121178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201631064T SI3356385T1 (sl) | 2015-09-30 | 2016-09-19 | 18F-označeni inhibitorji prostatnih membranskih antigenov (PSMA) in njihova uporaba kot slikovno prikazna sredstva za rak prostate |
Country Status (32)
Country | Link |
---|---|
US (3) | US10815200B2 (sl) |
EP (2) | EP3356385B1 (sl) |
JP (1) | JP6824971B2 (sl) |
KR (1) | KR102233726B1 (sl) |
CN (1) | CN108026144B (sl) |
AU (1) | AU2016333334B2 (sl) |
BR (1) | BR112018005899A2 (sl) |
CA (1) | CA2996330A1 (sl) |
CL (1) | CL2018000604A1 (sl) |
CO (1) | CO2018003726A2 (sl) |
CU (1) | CU24524B1 (sl) |
CY (1) | CY1123790T1 (sl) |
DK (1) | DK3356385T3 (sl) |
EA (1) | EA037512B1 (sl) |
ES (1) | ES2844586T3 (sl) |
GE (1) | GEP20207106B (sl) |
HR (1) | HRP20210183T1 (sl) |
HU (1) | HUE053064T2 (sl) |
IL (1) | IL258378B (sl) |
LT (1) | LT3356385T (sl) |
MX (1) | MX2018004050A (sl) |
MY (1) | MY197061A (sl) |
NZ (1) | NZ739770A (sl) |
PE (1) | PE20181350A1 (sl) |
PH (1) | PH12018500701B1 (sl) |
PL (1) | PL3356385T3 (sl) |
RS (1) | RS61394B1 (sl) |
SA (1) | SA518391121B1 (sl) |
SI (1) | SI3356385T1 (sl) |
TN (1) | TN2018000089A1 (sl) |
WO (1) | WO2017054907A1 (sl) |
ZA (1) | ZA201801024B (sl) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20207106B (en) * | 2015-09-30 | 2020-05-11 | Deutsches Krebsforsch | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer |
BR112019002560B1 (pt) | 2016-08-10 | 2022-08-16 | Cancer Targeted Technology Llc | Composto, composição farmacêutica, seus usos e método de preparação do mesmo |
DE102016122273B4 (de) * | 2016-11-18 | 2018-06-21 | Abx Advanced Biochemical Compounds Gmbh | Präkursoren für die Radiofluorierung |
MX2019005742A (es) * | 2016-11-23 | 2019-09-13 | Cancer Targeted Tech Llc | Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. |
CN110272468B (zh) * | 2019-05-14 | 2020-12-08 | 上海益泰医药科技有限公司 | 一种前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用 |
CN111253465A (zh) * | 2020-03-03 | 2020-06-09 | 复旦大学附属肿瘤医院 | 一种psma结合剂及其用途 |
CA3206250A1 (en) | 2021-02-08 | 2022-08-11 | Mark RIJPKEMA | Psma-targeting ligands for multimodal applications |
CA3227534A1 (en) * | 2021-07-30 | 2023-02-02 | Yoshifumi Shirakami | Radiolabeled compound and use thereof |
WO2023030434A1 (zh) * | 2021-09-01 | 2023-03-09 | 天津恒瑞医药有限公司 | 前列腺特异性膜抗原的抑制剂及其医药用途 |
CN118344391A (zh) * | 2023-01-13 | 2024-07-16 | 浙江普利药业有限公司 | 一种新的用于硼中子捕获疗法的含硼化合物 |
WO2025041103A1 (en) * | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Psma targeting ligands and methods of use |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2367787C (en) | 1999-04-28 | 2011-07-26 | Alan P. Kozikowski | Ligands for metabotropic glutamate receptors |
EP1409017A4 (en) | 2001-06-25 | 2006-05-24 | Drug Innovation & Design Inc | CELL TARGETING INVOLVING THE RECONNAISSANCE OF EXPONENTIAL FORMS, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS |
SI1472541T1 (sl) | 2002-01-10 | 2010-12-31 | Univ Johns Hopkins | Prikazovalni agensi in postopek prikazovanja naaladase ali psma |
WO2006093991A1 (en) | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
CA2668197A1 (en) | 2006-11-03 | 2008-05-15 | Philip S. Low | Ex vivo flow cytometry method and device |
ES2684322T3 (es) | 2006-11-08 | 2018-10-02 | Molecular Insight Pharmaceuticals, Inc. | Heterodímeros de ácido glutámico |
CN103372221B (zh) | 2007-01-11 | 2016-08-24 | 免疫医学股份有限公司 | 用于蛋白质、肽和其他分子的改进的f-18标记的方法和组合物 |
CA2926573C (en) | 2007-06-26 | 2018-08-28 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
ES2768224T3 (es) * | 2007-08-17 | 2020-06-22 | Purdue Research Foundation | Conjugados ligando-enlazador de unión a PSMA y métodos para su uso |
CA2891005A1 (en) | 2007-09-28 | 2008-10-09 | Bind Therapeutics, Inc. | Cancer cell targeting using nanoparticles |
WO2009070302A1 (en) | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
WO2009089383A2 (en) | 2008-01-09 | 2009-07-16 | Molecular Insight Pharmaceuticals, Inc. | Inhibitors of carbonic anhydrase ix |
CN102171187B (zh) | 2008-08-01 | 2017-07-28 | 约翰.霍普金斯大学 | Psma‑结合剂及其用途 |
TW201034691A (en) | 2008-12-05 | 2010-10-01 | Molecular Insight Pharm Inc | Technetium-and rhenium-bis(heteroaryl) complexes and methods of use thereof |
EP2706057B1 (en) | 2008-12-05 | 2016-04-20 | Molecular Insight Pharmaceuticals, Inc. | Bis(imidazolyl)compounds and radionuclide complexes |
FI3964502T3 (fi) | 2009-03-19 | 2024-07-29 | Univ Johns Hopkins | PSMA:han kohdentuvia yhdisteitä ja niiden käyttötarkoituksia |
GB0905438D0 (en) * | 2009-03-30 | 2009-05-13 | Ge Healthcare Ltd | Radiolabelling reagents and methods |
EP2338892A1 (en) * | 2009-12-18 | 2011-06-29 | Bayer Schering Pharma Aktiengesellschaft | Prostate specific membrane antigen inhibitors |
GB201020314D0 (en) | 2010-12-01 | 2011-01-12 | Ge Healthcare Ltd | Apoptosis pet imaging agents |
JP6275484B2 (ja) | 2010-12-06 | 2018-02-07 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | Psma標的化デンドリマー |
US20140308363A1 (en) | 2011-05-31 | 2014-10-16 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
EP2739316B1 (en) | 2011-08-05 | 2019-04-10 | Molecular Insight Pharmaceuticals, Inc. | Radiolabeled prostate specific membrane antigen inhibitors |
US10011632B2 (en) * | 2011-08-22 | 2018-07-03 | Siemens Medical Solutions Usa, Inc. | PSMA imaging agents |
US20140187501A1 (en) | 2012-12-28 | 2014-07-03 | Blend Therapeutics, Inc. | Targeted Conjugates Encapsulated in Particles and Formulations Thereof |
WO2014127365A1 (en) | 2013-02-15 | 2014-08-21 | Case Western Reserve University | Psma ligands and uses thereof |
WO2015004029A1 (en) | 2013-07-08 | 2015-01-15 | Technische Universität München | 18f-labeling of aromatic and heteroaromatic molecules with unprotected carboxylic acid groups |
US10406246B2 (en) | 2013-10-17 | 2019-09-10 | Deutsches Kresbsforschungszentrum | Double-labeled probe for molecular imaging and use thereof |
WO2015057250A1 (en) | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
ES2977715T3 (es) * | 2013-10-18 | 2024-08-29 | Novartis Ag | Inhibidores marcados de antígeno prostático específico de membrana (psma), su uso como agentes formadores de imágenes y agentes farmacéuticos para el tratamiento de cáncer de próstata |
BR112016010927A2 (pt) | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
US11124845B2 (en) | 2014-03-18 | 2021-09-21 | The Johns Hopkins University | PSMA-based molecular-genetic reporter system |
CN106660943B (zh) | 2014-05-06 | 2020-03-17 | 约翰霍普金斯大学 | 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物 |
WO2016030329A1 (en) | 2014-08-24 | 2016-03-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
CA2959726A1 (en) | 2014-09-08 | 2016-03-17 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in psma-targeted radionuclide therapy of prostate cancer |
EP3011976A1 (en) | 2014-10-20 | 2016-04-27 | Deutsches Krebsforschungszentrum | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents |
WO2016062370A1 (en) | 2014-10-20 | 2016-04-28 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
WO2016065142A2 (en) | 2014-10-22 | 2016-04-28 | The Johns Hopkins University | New scaffolds and multifunctional intermediates for imaging psma and cancer therapy |
GEP20207106B (en) * | 2015-09-30 | 2020-05-11 | Deutsches Krebsforsch | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer |
-
2016
- 2016-09-19 GE GEAP201614748A patent/GEP20207106B/en unknown
- 2016-09-19 PH PH1/2018/500701A patent/PH12018500701B1/en unknown
- 2016-09-19 JP JP2018516512A patent/JP6824971B2/ja active Active
- 2016-09-19 CU CU2018000030A patent/CU24524B1/es unknown
- 2016-09-19 PE PE2018000482A patent/PE20181350A1/es unknown
- 2016-09-19 BR BR112018005899-8A patent/BR112018005899A2/pt active Search and Examination
- 2016-09-19 DK DK16778680.5T patent/DK3356385T3/da active
- 2016-09-19 EP EP16778680.5A patent/EP3356385B1/en active Active
- 2016-09-19 RS RS20210120A patent/RS61394B1/sr unknown
- 2016-09-19 KR KR1020187012228A patent/KR102233726B1/ko active Active
- 2016-09-19 SI SI201631064T patent/SI3356385T1/sl unknown
- 2016-09-19 ES ES16778680T patent/ES2844586T3/es active Active
- 2016-09-19 MX MX2018004050A patent/MX2018004050A/es unknown
- 2016-09-19 MY MYPI2018700586A patent/MY197061A/en unknown
- 2016-09-19 LT LTEP16778680.5T patent/LT3356385T/lt unknown
- 2016-09-19 PL PL16778680T patent/PL3356385T3/pl unknown
- 2016-09-19 EP EP20206516.5A patent/EP3805250A1/en active Pending
- 2016-09-19 HU HUE16778680A patent/HUE053064T2/hu unknown
- 2016-09-19 TN TNP/2018/000089A patent/TN2018000089A1/en unknown
- 2016-09-19 AU AU2016333334A patent/AU2016333334B2/en active Active
- 2016-09-19 EA EA201890282A patent/EA037512B1/ru unknown
- 2016-09-19 CN CN201680054882.7A patent/CN108026144B/zh active Active
- 2016-09-19 NZ NZ739770A patent/NZ739770A/en unknown
- 2016-09-19 WO PCT/EP2016/001573 patent/WO2017054907A1/en active Application Filing
- 2016-09-19 CA CA2996330A patent/CA2996330A1/en active Pending
-
2018
- 2018-02-14 ZA ZA2018/01024A patent/ZA201801024B/en unknown
- 2018-03-08 US US15/915,978 patent/US10815200B2/en active Active
- 2018-03-08 CL CL2018000604A patent/CL2018000604A1/es unknown
- 2018-03-15 SA SA518391121A patent/SA518391121B1/ar unknown
- 2018-03-26 IL IL258378A patent/IL258378B/en active IP Right Grant
- 2018-04-06 CO CONC2018/0003726A patent/CO2018003726A2/es unknown
-
2020
- 2020-10-23 US US17/079,013 patent/US20210053922A1/en not_active Abandoned
-
2021
- 2021-02-01 CY CY20211100081T patent/CY1123790T1/el unknown
- 2021-02-02 HR HRP20210183TT patent/HRP20210183T1/hr unknown
-
2023
- 2023-03-17 US US18/186,043 patent/US12054458B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2400024I1 (hu) | A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére | |
HK1255215A1 (zh) | 用於成像和治療的尿素基前列腺特異性膜抗原(psma)抑制劑 | |
IL258378A (en) | Prostate-specific membrane antigen inhibitors are labeled with 18f and used as imaging agents for prostate cancer. | |
PT4095130T (pt) | Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata | |
IL251477A0 (en) | Anti-ang2 antibodies and methods of use | |
EP3201360A4 (en) | Methods for assessing risk of developing breast cancer | |
EP3152195A4 (en) | Mth1 inhibitors for treatment of cancer | |
HK1244445A1 (zh) | 使用抗-ang2抗體的方法 | |
SG10201913528PA (en) | Methods of diagnosing cancer | |
HK1243434A1 (zh) | Igf-1r抗體及其診斷癌症的用途 | |
HK1248730A1 (zh) | Igf-1r抗體及其用於癌症診斷的用途 | |
PT3356385T (pt) | Inibidores etiquetados com 18f de antigénio de membrana específico de próstata (psma) e utilização dos mesmos como agentes de imagiologia para o cancro da próstata |